SPR720: Potential to be the first approved novel oral agent for NTM.
SPR720 is a broad spectrum, oral candidate that, if approved, may be applicable to both non-refractory and refractory patients. Once daily dosing is supported by clinical and non-clinical studies.
SPR720: Potential to address a large unmet need in NTM disease.
In NTM, treatment failure is common and the current treatment for NTM is lengthy and involves combination therapy, often including three or more antibiotics, including injectables.
NTM Info & Research is a 501(c)(3) non-profit organization formed for patient support, medical education and to help accelerate research.
Patients can follow the progress of SPR720 as the candidate moves through clinical trials. ClinicalTrials.gov is a database of clinical studies conducted worldwide.